The dual GLP-1 and glucagon receptor agonist resulted in striking weight loss in a phase 2 dosing trial of people with overweight or obesity but without type 2 diabetes.
CagriSema (cagrilintide plus semaglutide) led to weight loss of a magnitude not previously reported with pharmacotherapies in type 2 diabetes, plus improved CGM measures, in a phase 2 trial.
The investigational GLP-1 agonist, taken as an oral tablet, works similarly to other drugs in the class for reducing body weight and improving glucose, without needing to be taken on an empty stomach.